Unveiling the therapeutic potential and mechanisms of stanniocalcin-1 in retinal degeneration

Retinal degeneration (RD) is a group of ocular diseases characterized by progressive photoreceptor apoptosis and visual impairment. Mitochondrial malfunction, excessive oxidative stress, and chronic activation of neuroglia collectively contribute to the development of RD. Currently, there is a lack...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Survey of ophthalmology 2025-01, Vol.70 (1), p.106-120
Hauptverfasser: Wang, Kexin, Liu, Yashuang, Li, Siyu, Zhao, Na, Qin, Fangyuan, Tao, Ye, Song, Zongming
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 120
container_issue 1
container_start_page 106
container_title Survey of ophthalmology
container_volume 70
creator Wang, Kexin
Liu, Yashuang
Li, Siyu
Zhao, Na
Qin, Fangyuan
Tao, Ye
Song, Zongming
description Retinal degeneration (RD) is a group of ocular diseases characterized by progressive photoreceptor apoptosis and visual impairment. Mitochondrial malfunction, excessive oxidative stress, and chronic activation of neuroglia collectively contribute to the development of RD. Currently, there is a lack of efficacious therapeutic interventions for RD. Stanniocalcin-1 (STC-1) is a promising candidate molecule to decelerate photoreceptor cell death. STC-1 is a secreted calcium/phosphorus regulatory protein that exerts diverse protective effects. Accumulating evidence suggests that STC-1 protects retinal cells from ischemic injury, oxidative stress, and excessive apoptosis through enhancing the expression of uncoupling protein-2 (UCP-2). Furthermore, STC-1 exerts its antiinflammatory effects by inhibiting the activation of microglia and macrophages, as well as the synthesis and secretion of proinflammatory cytokines, such as TNF-α, IL-1, and IL-6. By employing these mechanisms, STC-1 effectively shields the retinal photoreceptors and optic nerve, thereby slowing down the progression of RD. We summarize the STC-1-mediated therapeutic effects on the degenerating retina, with a particular focus on its underlying mechanisms. These findings highlight that STC-1 may act as a versatile molecule to treat degenerative retinopathy. Further research on STC-1 is imperative to establish optimal protocols for its clinical use.
doi_str_mv 10.1016/j.survophthal.2024.08.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3104537230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0039625724000857</els_id><sourcerecordid>3104537230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1666-bd2a278fdeb7bffcbcfd9a31ba82fb8f9f23caa2687dab6cdada7822a1f5deb13</originalsourceid><addsrcrecordid>eNqNkE1r3DAQhkVoSDZp_0Jxb73Y0ceuJR_L0iSFQC7JMYixNMpqsSVXkhf67-Nl09JjDsNcnvcd5iHkG6MNo6y92Td5Toc47coOhoZTvm6oaihlZ2TFlOxqIej6E1lRKrq65Rt5Sa5y3lNK16KTF-RSdFxSxdsVeXkOB_SDD69V2eFxEkw4F2-qKRYMxcNQQbDViGYHwecxV9FVuUAIPhoYjA81q3yoEhYfFtjiK4alpfgYPpNzB0PGL-_7mjzf_nza3tcPj3e_tj8easPatq17y4FL5Sz2snfO9MbZDgTrQXHXK9c5LgwAb5W00LfGggWpOAfmNkuGiWvy_dQ7pfh7xlz06LPBYYCAcc5aMLreCMkFXdDuhJoUc07o9JT8COmPZlQf7eq9_s-uPtrVVOnF7pL9-n5m7ke0_5J_dS7A9gTg8uzBY9LZeAwGrU9oirbRf-DMG5TJlbY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3104537230</pqid></control><display><type>article</type><title>Unveiling the therapeutic potential and mechanisms of stanniocalcin-1 in retinal degeneration</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Wang, Kexin ; Liu, Yashuang ; Li, Siyu ; Zhao, Na ; Qin, Fangyuan ; Tao, Ye ; Song, Zongming</creator><creatorcontrib>Wang, Kexin ; Liu, Yashuang ; Li, Siyu ; Zhao, Na ; Qin, Fangyuan ; Tao, Ye ; Song, Zongming</creatorcontrib><description>Retinal degeneration (RD) is a group of ocular diseases characterized by progressive photoreceptor apoptosis and visual impairment. Mitochondrial malfunction, excessive oxidative stress, and chronic activation of neuroglia collectively contribute to the development of RD. Currently, there is a lack of efficacious therapeutic interventions for RD. Stanniocalcin-1 (STC-1) is a promising candidate molecule to decelerate photoreceptor cell death. STC-1 is a secreted calcium/phosphorus regulatory protein that exerts diverse protective effects. Accumulating evidence suggests that STC-1 protects retinal cells from ischemic injury, oxidative stress, and excessive apoptosis through enhancing the expression of uncoupling protein-2 (UCP-2). Furthermore, STC-1 exerts its antiinflammatory effects by inhibiting the activation of microglia and macrophages, as well as the synthesis and secretion of proinflammatory cytokines, such as TNF-α, IL-1, and IL-6. By employing these mechanisms, STC-1 effectively shields the retinal photoreceptors and optic nerve, thereby slowing down the progression of RD. We summarize the STC-1-mediated therapeutic effects on the degenerating retina, with a particular focus on its underlying mechanisms. These findings highlight that STC-1 may act as a versatile molecule to treat degenerative retinopathy. Further research on STC-1 is imperative to establish optimal protocols for its clinical use.</description><identifier>ISSN: 0039-6257</identifier><identifier>ISSN: 1879-3304</identifier><identifier>EISSN: 1879-3304</identifier><identifier>DOI: 10.1016/j.survophthal.2024.08.001</identifier><identifier>PMID: 39270826</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Apoptosis ; Apoptotic ; Glycoproteins - metabolism ; Glycoproteins - therapeutic use ; Humans ; Inflammatory response ; Oxidative stress ; Oxidative Stress - physiology ; Retinal degeneration ; Retinal Degeneration - metabolism ; Stanniocalcin-1</subject><ispartof>Survey of ophthalmology, 2025-01, Vol.70 (1), p.106-120</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1666-bd2a278fdeb7bffcbcfd9a31ba82fb8f9f23caa2687dab6cdada7822a1f5deb13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.survophthal.2024.08.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39270826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Kexin</creatorcontrib><creatorcontrib>Liu, Yashuang</creatorcontrib><creatorcontrib>Li, Siyu</creatorcontrib><creatorcontrib>Zhao, Na</creatorcontrib><creatorcontrib>Qin, Fangyuan</creatorcontrib><creatorcontrib>Tao, Ye</creatorcontrib><creatorcontrib>Song, Zongming</creatorcontrib><title>Unveiling the therapeutic potential and mechanisms of stanniocalcin-1 in retinal degeneration</title><title>Survey of ophthalmology</title><addtitle>Surv Ophthalmol</addtitle><description>Retinal degeneration (RD) is a group of ocular diseases characterized by progressive photoreceptor apoptosis and visual impairment. Mitochondrial malfunction, excessive oxidative stress, and chronic activation of neuroglia collectively contribute to the development of RD. Currently, there is a lack of efficacious therapeutic interventions for RD. Stanniocalcin-1 (STC-1) is a promising candidate molecule to decelerate photoreceptor cell death. STC-1 is a secreted calcium/phosphorus regulatory protein that exerts diverse protective effects. Accumulating evidence suggests that STC-1 protects retinal cells from ischemic injury, oxidative stress, and excessive apoptosis through enhancing the expression of uncoupling protein-2 (UCP-2). Furthermore, STC-1 exerts its antiinflammatory effects by inhibiting the activation of microglia and macrophages, as well as the synthesis and secretion of proinflammatory cytokines, such as TNF-α, IL-1, and IL-6. By employing these mechanisms, STC-1 effectively shields the retinal photoreceptors and optic nerve, thereby slowing down the progression of RD. We summarize the STC-1-mediated therapeutic effects on the degenerating retina, with a particular focus on its underlying mechanisms. These findings highlight that STC-1 may act as a versatile molecule to treat degenerative retinopathy. Further research on STC-1 is imperative to establish optimal protocols for its clinical use.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptotic</subject><subject>Glycoproteins - metabolism</subject><subject>Glycoproteins - therapeutic use</subject><subject>Humans</subject><subject>Inflammatory response</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - physiology</subject><subject>Retinal degeneration</subject><subject>Retinal Degeneration - metabolism</subject><subject>Stanniocalcin-1</subject><issn>0039-6257</issn><issn>1879-3304</issn><issn>1879-3304</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1r3DAQhkVoSDZp_0Jxb73Y0ceuJR_L0iSFQC7JMYixNMpqsSVXkhf67-Nl09JjDsNcnvcd5iHkG6MNo6y92Td5Toc47coOhoZTvm6oaihlZ2TFlOxqIej6E1lRKrq65Rt5Sa5y3lNK16KTF-RSdFxSxdsVeXkOB_SDD69V2eFxEkw4F2-qKRYMxcNQQbDViGYHwecxV9FVuUAIPhoYjA81q3yoEhYfFtjiK4alpfgYPpNzB0PGL-_7mjzf_nza3tcPj3e_tj8easPatq17y4FL5Sz2snfO9MbZDgTrQXHXK9c5LgwAb5W00LfGggWpOAfmNkuGiWvy_dQ7pfh7xlz06LPBYYCAcc5aMLreCMkFXdDuhJoUc07o9JT8COmPZlQf7eq9_s-uPtrVVOnF7pL9-n5m7ke0_5J_dS7A9gTg8uzBY9LZeAwGrU9oirbRf-DMG5TJlbY</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Wang, Kexin</creator><creator>Liu, Yashuang</creator><creator>Li, Siyu</creator><creator>Zhao, Na</creator><creator>Qin, Fangyuan</creator><creator>Tao, Ye</creator><creator>Song, Zongming</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202501</creationdate><title>Unveiling the therapeutic potential and mechanisms of stanniocalcin-1 in retinal degeneration</title><author>Wang, Kexin ; Liu, Yashuang ; Li, Siyu ; Zhao, Na ; Qin, Fangyuan ; Tao, Ye ; Song, Zongming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1666-bd2a278fdeb7bffcbcfd9a31ba82fb8f9f23caa2687dab6cdada7822a1f5deb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptotic</topic><topic>Glycoproteins - metabolism</topic><topic>Glycoproteins - therapeutic use</topic><topic>Humans</topic><topic>Inflammatory response</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - physiology</topic><topic>Retinal degeneration</topic><topic>Retinal Degeneration - metabolism</topic><topic>Stanniocalcin-1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Kexin</creatorcontrib><creatorcontrib>Liu, Yashuang</creatorcontrib><creatorcontrib>Li, Siyu</creatorcontrib><creatorcontrib>Zhao, Na</creatorcontrib><creatorcontrib>Qin, Fangyuan</creatorcontrib><creatorcontrib>Tao, Ye</creatorcontrib><creatorcontrib>Song, Zongming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Survey of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Kexin</au><au>Liu, Yashuang</au><au>Li, Siyu</au><au>Zhao, Na</au><au>Qin, Fangyuan</au><au>Tao, Ye</au><au>Song, Zongming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unveiling the therapeutic potential and mechanisms of stanniocalcin-1 in retinal degeneration</atitle><jtitle>Survey of ophthalmology</jtitle><addtitle>Surv Ophthalmol</addtitle><date>2025-01</date><risdate>2025</risdate><volume>70</volume><issue>1</issue><spage>106</spage><epage>120</epage><pages>106-120</pages><issn>0039-6257</issn><issn>1879-3304</issn><eissn>1879-3304</eissn><abstract>Retinal degeneration (RD) is a group of ocular diseases characterized by progressive photoreceptor apoptosis and visual impairment. Mitochondrial malfunction, excessive oxidative stress, and chronic activation of neuroglia collectively contribute to the development of RD. Currently, there is a lack of efficacious therapeutic interventions for RD. Stanniocalcin-1 (STC-1) is a promising candidate molecule to decelerate photoreceptor cell death. STC-1 is a secreted calcium/phosphorus regulatory protein that exerts diverse protective effects. Accumulating evidence suggests that STC-1 protects retinal cells from ischemic injury, oxidative stress, and excessive apoptosis through enhancing the expression of uncoupling protein-2 (UCP-2). Furthermore, STC-1 exerts its antiinflammatory effects by inhibiting the activation of microglia and macrophages, as well as the synthesis and secretion of proinflammatory cytokines, such as TNF-α, IL-1, and IL-6. By employing these mechanisms, STC-1 effectively shields the retinal photoreceptors and optic nerve, thereby slowing down the progression of RD. We summarize the STC-1-mediated therapeutic effects on the degenerating retina, with a particular focus on its underlying mechanisms. These findings highlight that STC-1 may act as a versatile molecule to treat degenerative retinopathy. Further research on STC-1 is imperative to establish optimal protocols for its clinical use.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39270826</pmid><doi>10.1016/j.survophthal.2024.08.001</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0039-6257
ispartof Survey of ophthalmology, 2025-01, Vol.70 (1), p.106-120
issn 0039-6257
1879-3304
1879-3304
language eng
recordid cdi_proquest_miscellaneous_3104537230
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Apoptosis
Apoptotic
Glycoproteins - metabolism
Glycoproteins - therapeutic use
Humans
Inflammatory response
Oxidative stress
Oxidative Stress - physiology
Retinal degeneration
Retinal Degeneration - metabolism
Stanniocalcin-1
title Unveiling the therapeutic potential and mechanisms of stanniocalcin-1 in retinal degeneration
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A07%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unveiling%20the%20therapeutic%20potential%20and%20mechanisms%20of%20stanniocalcin-1%20in%20retinal%20degeneration&rft.jtitle=Survey%20of%20ophthalmology&rft.au=Wang,%20Kexin&rft.date=2025-01&rft.volume=70&rft.issue=1&rft.spage=106&rft.epage=120&rft.pages=106-120&rft.issn=0039-6257&rft.eissn=1879-3304&rft_id=info:doi/10.1016/j.survophthal.2024.08.001&rft_dat=%3Cproquest_cross%3E3104537230%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3104537230&rft_id=info:pmid/39270826&rft_els_id=S0039625724000857&rfr_iscdi=true